antibody levels and vaccination attitude after asymptomatic to moderate

omniscientis

omniscientis

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

 

Regardless of substantial progress in confronting the worldwide HIV-1 epidemic since its inception within the 1980s, higher approaches for each therapy and prevention will probably be obligatory to finish the epidemic and stay a high public well being precedence. Antiretroviral remedy (ART) has been efficient in extending lives, however at a price of lifelong adherence to therapy. Broadly neutralizing antibodies (bNAbs) are directed to conserved areas of the HIV-1 envelope glycoprotein trimer (Env) and may block an infection if current on the time of viral publicity. The therapeutic software of bNAbs holds nice promise, and progress is being made towards their growth for widespread medical use. In comparison with the present customary of care of small molecule-based ART, bNAbs supply: (1) decreased toxicity; (2) the benefits of prolonged half-lives that might bypass day by day dosing necessities; and (3) the potential to include a wider immune response by Fc signaling. Latest advances in discovery expertise can allow system-wide mining of the immunoglobulin repertoire and can proceed to speed up isolation of subsequent era potent bNAbs. Passive switch research in pre-clinical fashions and medical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and attaining viral suppression.

These research have helped to outline the window of alternative for optimum intervention to realize viral clearance, both utilizing bNAbs alone or together with ART. None of those advances with bNAbs can be doable with out technological developments and increasing the cohorts of donor participation. Collectively these components fueled the exceptional development in bNAb growth. Right here, we evaluation the event of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal fashions and early medical trials, and improvements to optimize their medical potential by efforts to increase half-life, maximize the contribution of Fc effector capabilities, preclude escape by multiepitope concentrating on, and the potential for sustained supply.

 

Signs, antibody ranges and vaccination perspective after asymptomatic to reasonable COVID-19 an infection in 200 healthcare employees

 

Purpose: In Germany, the willingness to be vaccinated towards COVID-19 is slightly low amongst medical workers. We collected information on signs, antibody titers and vaccination readiness from clinic workers at a municipal clinic who had already been by a COVID-19 an infection (asymptomatic to reasonable). We additionally examined the antibody titers for his or her doable significance as a person decision-making assist with regard to vaccination.

 

Technique: 200 workers of our municipal clinics have been included within the research. COVID-19 antibody dedication was carried out utilizing an ELISA (EUROIMMUN™, PerkinElmer, Inc. Firm). The individuals got an nameless questionnaire containing anthropometrical points, signs of the an infection and questions in regards to the vaccination resolution. Lastly, the antibody ranges have been reported to the individuals and the perspective in the direction of a vaccination was reevaluated.

 

Outcomes: In all 200 individuals who had already gone by a COVID-19 an infection, 75 workers have been in favor of a vaccination (37.5%), 96 have been against vaccination (48%), and 29 have been undecided (14.5%). Within the completely different occupational teams, the constructive pattern by way of willingness to be vaccinated was highest amongst physicians and is least amongst nurses. The antibody outcomes confirmed appreciable variation in titer ranges and subsequently didn’t correlate with illness severity in asymptomatic to reasonably in poor health individuals. We additionally noticed a pro-vaccination pattern with rising age of the individuals. The specifically-asked symptom of cutaneous hyperesthesia throughout COVID-19 an infection occurred in 5% of the individuals.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 an infection, the willingness to obtain a vaccination tends to be highest amongst physicians, and lowest in nurses, and will increase with age. For the overwhelming majority of these affected, data of the antibody titers solely reinforces the vaccination resolution made beforehand and thus doesn’t contribute to a change in vaccination resolution. The specifically-requested symptom of cutaneous hyperesthesia throughout COVID-19 an infection was unexpectedly frequent.

omniscientis
omniscientis

Anti-VEGF antibody

PAab09391 100 ug
EUR 463.2

anti- VEGF antibody

FNab09391 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti- VEGF antibody

FNab09933 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti-VEGF antibody

STJ97787 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF.

Anti-VEGF antibody

STJ119887 100 µl
EUR 471.6
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 336

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 336

Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin

1-CSB-EP606027NAH
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli

Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug

7422-MSM1-P1 100ug
EUR 513.6

Anti-VEGF-C Antibody

A00623 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat.

Anti-VEGF/Vegfa Antibody

A00045 100ug/vial
EUR 352.8

Anti-VEGF/VEGF164 Antibody

A00045-1 100ug/vial
EUR 352.8

Anti-VEGF/Vegfa Antibody

A00045-2 100ug/vial
EUR 352.8

Anti-VEGF/VEGFA Antibody

PA1080 100ug/vial
EUR 400.8

Anti-VEGF/VEGFA Antibody

PB9071 100ug/vial
EUR 400.8

Anti-VEGF-C antibody

STJ96662 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF-C.

Anti-VEGF-B antibody

STJ96851 200 µl
EUR 236.4
Description: Rabbit polyclonal to VEGF-B.

anti-VEGF Receptor 3

YF-PA23727 50 ul
EUR 400.8
Description: Mouse polyclonal to VEGF Receptor 3

anti-VEGF Receptor 1

YF-PA11817 50 ug
EUR 435.6
Description: Mouse polyclonal to VEGF Receptor 1

anti-VEGF Receptor 1

YF-PA11818 100 ug
EUR 483.6
Description: Rabbit polyclonal to VEGF Receptor 1

VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled

AP-334-F 1 mg Ask for price

anti-Cyclophilin F

YF-PA25484 50 ul
EUR 400.8
Description: Mouse polyclonal to Cyclophilin F

anti-Apolipoprotein F

YF-PA10244 50 ul
EUR 435.6
Description: Mouse polyclonal to Apolipoprotein F

anti-Apolipoprotein F

YF-PA10245 50 ug
EUR 435.6
Description: Mouse polyclonal to Apolipoprotein F

anti-Apolipoprotein F

YF-PA10246 100 ug
EUR 483.6
Description: Rabbit polyclonal to Apolipoprotein F

anti-Cathepsin F

YF-PA15821 50 ul
EUR 435.6
Description: Mouse polyclonal to Cathepsin F

anti-Cathepsin F

YF-PA15822 50 ug
EUR 435.6
Description: Mouse polyclonal to Cathepsin F

VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled

AP-336-F 1 mg Ask for price

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-b-48T 48T
EUR 591.6
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-b-96T 96T
EUR 769.2
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Hu-48T 48T
EUR 403.2
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Hu-96T 96T
EUR 510
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Mu-48T 48T
EUR 522
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Mu-96T 96T
EUR 673.2
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Ra-48T 48T
EUR 544.8
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Ra-96T 96T
EUR 704.4
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-b-48Tests 48 Tests
EUR 619.2

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-b-96Tests 96 Tests
EUR 859.2

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Hu-48Tests 48 Tests
EUR 396

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Hu-96Tests 96 Tests
EUR 540

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Mu-48Tests 48 Tests
EUR 536.4

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Mu-96Tests 96 Tests
EUR 741.6

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Ra-48Tests 48 Tests
EUR 564

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Ra-96Tests 96 Tests
EUR 781.2

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-b-48Tests 48 Tests
EUR 592.8

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-b-96Tests 96 Tests
EUR 820.8

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Hu-48Tests 48 Tests
EUR 380.4

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Hu-96Tests 96 Tests
EUR 517.2

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Mu-48Tests 48 Tests
EUR 514.8

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Mu-96Tests 96 Tests
EUR 709.2

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Ra-48Tests 48 Tests
EUR 540

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Ra-96Tests 96 Tests
EUR 746.4

VEGF

MO15067 500 ug
EUR 1092

VEGF

LF-PR009 10 ug
EUR 306
Description: VEGF protein

VEGF

PR15028 10 ug
EUR 553.2

Anti-VEGF (Bevacizumab), humanized Antibody

A1045-100
EUR 601.2

Anti-VEGF-A Humanized Antibody

A2136-100 100 µg
EUR 612

Anti-VEGF Rabbit Monoclonal Antibody

M00045-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse.

Anti-VEGF Receptor 2 (2A2)

YF-MA13909 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4A2)

YF-MA13910 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (2C5)

YF-MA13911 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4B5)

YF-MA13912 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4F1)

YF-MA13913 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 3 (5B6)

YF-MA10355 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5F11)

YF-MA13094 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6F9)

YF-MA13095 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5B5)

YF-MA13096 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (4D1)

YF-MA13097 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (2E3)

YF-MA13098 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (1C1)

YF-MA13099 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6B7)

YF-MA13100 100 ug
EUR 435.6
Description: Mouse monoclonal to VEGF Receptor 3

VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled

AP-335-F 1 mg Ask for price

VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled

AP-338-F 1 mg Ask for price

VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled

AP-339-F 1 mg Ask for price

Mouse IgG F(c)-FITC conjugate (isotype control)

20008-Fc-F 100 ug
EUR 196.8

Rabbit IgG F(c)-FITC conjugate, isotype control

20009-Fc-F 100 ug
EUR 196.8

Goat IgG F(ab')2 fragment-FITC conjugate

20011-FAB2-F 100 tests
EUR 242.4

VEGF-A(VEGF/1063) Antibody

BNC041063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC041063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCP1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCR1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCA1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-100 100uL
EUR 250.8
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-500 500uL
EUR 549.6
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC401063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC401063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNUM1063-50 50uL
EUR 474
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF/ Rat VEGF ELISA Kit

ELA-E0143r 96 Tests
EUR 1063.2

Mouse IgG F(ab')2-FITC conjugate (isotype control)

20008-Fab2-F 100 ug
EUR 196.8

Rabbit IgG F(ab')2-FITC conjugate, isotype control

20009-FAb2-F 100 ug
EUR 196.8

Anti-HLA-F Purified

11-823-C100 0.1 mg
EUR 234

Anti-Cyclin F Antibody

A06781 100ul
EUR 476.4
Description: Rabbit Polyclonal Cyclin F Antibody. Validated in IHC, WB and tested in Human.

Anti-HLA-F PE

1P-823-C100 0.1 mg
EUR 397.2

Anti-Cathepsin F antibody

PAab01307 100 ug
EUR 426

Anti-Cystatin F antibody

PAab02182 100 ug
EUR 463.2

Anti-HLA-F antibody

PAab03911 100 ug
EUR 494.4

Anti-HLA-F antibody

PAab03912 100 ug
EUR 494.4

anti- Cathepsin F antibody

FNab01307 100µg
EUR 606.3
Description: Antibody raised against Cathepsin F

anti- Cystatin F antibody

FNab02182 100µg
EUR 658.5
Description: Antibody raised against Cystatin F

anti- HLA-F antibody

FNab03911 100µg
EUR 702
Description: Antibody raised against HLA-F

anti- HLA-F antibody

FNab03912 100µg
EUR 702
Description: Antibody raised against HLA-F

Anti-HLA-F antibody

STJ112420 100 µl
EUR 332.4
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.

Anti-APOBEC3D/F antibody

STJ91636 200 µl
EUR 236.4
Description: Rabbit polyclonal to APOBEC3D/F.

Anti-Arylsulfatase F antibody

STJ91715 200 µl
EUR 236.4
Description: Rabbit polyclonal to Arylsulfatase F.

Anti-Cyclin F antibody

STJ92545 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cyclin F.

Anti-Cyclophilin F antibody

STJ92550 200 µl
EUR 236.4
Description: Rabbit polyclonal to Cyclophilin F.

Anti-F beta antibody

STJ93162 200 µl
EUR 236.4
Description: Rabbit polyclonal to FTbeta.

Anti-hnRNP F antibody

STJ93564 200 µl
EUR 236.4
Description: Rabbit polyclonal to hnRNP F.

Anti-PIG-F antibody

STJ95089 200 µl
EUR 236.4
Description: Rabbit polyclonal to PIG-F.

Anti-Cathepsin F antibody

STJ70694 100 µg
EUR 430.8

Anti-HLA-F antibody

STJ24030 100 µl
EUR 332.4
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.

Anti-Apolipoprotein F antibody

STJ71651 100 µg
EUR 430.8

Anti-Apolipoprotein F (1D5)

YF-MA10047 100 ug
EUR 435.6
Description: Mouse monoclonal to Apolipoprotein F

Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA

570-100-CUX Custom Ask for price

Anti-VEGF Receptor 3/FLT4 Antibody

A01276-2 100ug/vial
EUR 400.8

Anti-VEGF Receptor 3/FLT4 Antibody

A01276-3 100ug/vial
EUR 400.8

Anti-VEGF Receptor 1/FLT1 Antibody

A00534 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody

A00534-1 100ug/vial
EUR 352.8

Anti-VEGF Receptor 2/KDR Antibody

A00901-2 100ug/vial
EUR 400.8

Anti-VEGF Receptor 2/Kdr Antibody

A00901-3 100ug/vial
EUR 400.8

Anti-VEGF Receptor 1/FLT1 Antibody

PA1399 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966-1 100ug/vial
EUR 352.8

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966-2 100ug/vial
EUR 352.8

Anti-VEGF Receptor 2/KDR Antibody

PA1989 100ug/vial
EUR 400.8

Anti-VEGF Receptor 2/KDR Antibody

PB9429 100ug/vial
EUR 352.8

VEGF antibody

70R-11863 100 ul
EUR 536.4
Description: Goat polyclonal VEGF antibody

VEGF antibody

70R-11864 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12327 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12328 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12329 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF Antibody

5363-100
EUR 398.4

VEGF Antibody

5363-30T
EUR 175.2

VEGF Antibody

5365-100
EUR 379.2

VEGF Antibody

5365-30T
EUR 175.2

VEGF antibody

70-VR20 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

10-2585 250 ug
EUR 590.4
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10-2586 100 ug
EUR 289.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

70R-13764 100 ug
EUR 418.8
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody

48707-100ul 100ul
EUR 399.6

VEGF Antibody

48707-50ul 50ul
EUR 286.8

VEGF protein

30R-AV008 2 ug
EUR 152.4
Description: Purified recombinant Murine VEGF protein

VEGF antibody

10R-7735 500 ug
EUR 678
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101ax 100 ug
EUR 571.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101b 200 ug
EUR 805.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V109A 500 ug
EUR 327.6
Description: Mouse monoclonal VEGF antibody

VEGF Antibody

ABF5131 100 ug
EUR 525.6

VEGF antibody

70R-VG001 100 ug
EUR 392.4
Description: Affinity purified Goat polyclonal VEGF antibody

VEGF antibody

70R-VR001x 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR003 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR004 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR006 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

PAab09933 100 ug
EUR 463.2

VEGF, CF

PR15028CF 10 ug
EUR 553.2

 

Engineering a novel IgG-like bispecific antibody towards enterovirus A71

 

Frequent outbreaks of enterovirus A71 (EVA71) happen within the Asia-Pacific space, and these are carefully related to extreme neurological signs in younger kids. No efficient antiviral remedy is at present accessible for the therapy of EVA71 an infection. The event of monoclonal antibodies (mAbs) has demonstrated promise as a novel remedy for the prevention and therapy of infectious illnesses. A number of medical situations have been handled utilizing bispecific or multi-specific antibodies that acknowledge two or extra distinct epitopes concurrently. Nevertheless, bispecific or multi-specific antibodies typically encounter protein expression and product stability issues.

On this research, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral exercise in contrast with E18 or F1. Moreover, E18-F1 not solely improved survival price, but in addition decreased medical indicators in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a deadly dose of EVA71. Altogether, our outcomes reveal that E18-F1 is a straightforward format bispecific antibody with promising antiviral exercise for EVA71.

Excessive antibody ranges towards human herpesvirus-6A work together with life-style elements in a number of sclerosis growth

 

Background: An infection with human herpesvirus 6A (HHV-6A) has been instructed to extend a number of sclerosis (MS) danger. Nevertheless, potential interactions between HHV-6A and environmental/life-style danger elements for MS haven’t beforehand been studied.

Strategies: We used two Swedish population-based case-control research comprising 5993 circumstances and 5995 controls. Utilizing logistic regression fashions, topics with completely different HHV-6A antibody ranges, environmental exposures, and life-style habits have been in contrast concerning MS danger, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between excessive HHV-6A antibody ranges and customary environmental exposures and life-style elements have been evaluated on the additive scale.

Outcomes: Excessive HHV-6A antibody ranges have been related to elevated danger of creating MS (OR = 1.5, 95% CI = 1.4-1.6). Concerning MS danger, vital interactions have been noticed between excessive HHV-6A antibody ranges and each smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) publicity (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D ranges (AP = 0.3, 95% CI = 0.0-0.6).

Conclusion: Excessive HHV-6A antibody ranges are related to elevated MS danger and act synergistically with widespread environmental/life-style danger elements for MS. Additional analysis is required to analyze potential mechanisms underlying the interactions introduced on this research.

 

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *